Trials / Terminated
TerminatedNCT00197145
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW873140 | 400 mg twice daily |
Timeline
- Start date
- 2005-07-21
- Primary completion
- 2007-09-11
- Completion
- 2007-09-11
- First posted
- 2005-09-20
- Last updated
- 2018-11-02
- Results posted
- 2018-11-02
Locations
55 sites across 3 countries: United States, Canada, Puerto Rico
Source: ClinicalTrials.gov record NCT00197145. Inclusion in this directory is not an endorsement.